Next Generation Sequencing

Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms [COVID-19 Series]

Lowest Price Guaranteed From USD 4,499
Published
December 2019
Pages
381
View Count
18353
Buy Now

Example Insights

Report Description

[COVID-19 SERIES] The current market of next generation sequencing (NGS) is estimated to be worth $3,593 million, and is likely to grow to $19,402 million by 2030. Advances in DNA sequencing technologies have led to significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Particularly, the impact of next generation sequencing (NGS) methods, enabling whole genome and whole exome sequencing, has been the most profound. This high throughput, parallel genome sequencing technology has greatly reduced the overall cost and time investment. In fact, compared to the Human Genome Project (~USD 3 billion), the cost of sequencing a single genome has decreased to USD 1,000, using currently available technologies. Owing to the ongoing innovation in this field, stakeholders believe that the aforementioned cost may get further reduced to USD 100 over the next decade. This decrease in genome sequencing costs has led to a marked increase in the number of genomes being sequenced around the world. In fact, several large scale efforts, such as UK Biobank and GenomeAsia 100k, have been initiated in order to collect genomic data for use in medical research. Big pharma players, including AstraZeneca, GSK, Pfizer, Merck and Roche, are actively on the lookout for collaborating with such data repositories in order to access the aforementioned information.

Despite the progress made in this field of research, there are several existing challenges related to the NGS process affiliated workflow and data analysis. The lack of versatile in silico tools is considered to be the major rate-limiting step in NGS data analysis and interpretations. At present, industry stakeholders are actively collaborating in order to integrate their respective resources for mining these large and complex datasets to generate clinically relevant, actionable insights. Additionally, there is a need for better genomic library preparation protocols, which required less starting material, and are capable of generating libraries with more precisely estimated insert sizes and longer reads at reduced error rates. More efficient genome assembly algorithms and better processors (increased computational power) for genomic data processing are also likely to get developed. We are led to believe that, once the aforementioned challenges are addressed, this segment of the biopharmaceutical industry will witness significant growth.

Scope of the Report

The ‘Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms’ report features an extensive study of the current landscape and the future opportunities associated with service / technologies providers. Amongst other elements, the report features:

An overview of the genome sequencing service providers landscape, featuring information on year of establishment, company size, geographical location and types of services offered (sanger sequencing, genotyping, whole genome sequencing, whole exome sequencing targeted sequencing and bioinformatics). Further, it provides details on the cost of services, sequencing systems used, average turn-around time and sequencing coverage, for certain types of sequencing-related services (whole genome, whole exome and targeted sequencing) offered by contract service providers.
An overview of genome sequencing technologies landscape, featuring information on type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in this domain, including information on year of establishment, company size and geographical location.
An informed competitiveness analysis of the genome sequencing technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as types of applications, maximum sequencing output, maximum reads per run, maximum read length, quality score and cost of sequencer.
An in-depth analysis of intellectual property related to this field of research, in order to generate an opinion on how the industry has evolved from the R&D perspective. The analysis takes into consideration genome sequencing-related patents that have been filed / granted since 2015, highlighting publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players, patent characteristics and geography.
An analysis of completed, ongoing and planned clinical studies related to genome sequencing, featuring details on registration year, type of sponsors / collaborators, current status of trials, type of study design, target therapeutic area, type of application, regional distribution of clinical trials and enrolled patient population.
An analysis of the various genome sequencing-focused initiatives of the ten big pharma players (shortlisted based on extent of activity in genome sequencing domain), highlighting the key focus areas of such companies along with information on funding, collaboration and acquisition activity.
A case study on the various national and international, government sponsored initiatives related to genome sequencing, analyzed on the basis of year of initiation, type of investors, type of participant organization, research objectives, geographical distribution, region-specific data access policies and key focus areas of research.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the genome sequencing services and technologies market. Based on several parameters, such as number of genomes sequenced annually, average cost of sequencing, revenues generated by major players and expected annual growth rate, we have provided an informed estimate of the likely evolution of the market, for the period 2020-2030. The chapter also presents a detailed segmentation of the aforementioned opportunity across [A] key application areas (diagnostics, drug discovery, precision medicine and others), [B] end-users (hospitals and clinics, academics and research institutes, pharmaceuticals companies and others), [C] types of technologies (sequencing by synthesis, ion semiconductor, single-molecule real-time sequencing, nanopore and others), [D] types of services (whole genome sequencing, whole exome sequencing and targeted sequencing) and [E] key geographical regions (North America, Asia-Pacific, Europe, and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

Michael Powell (Chief Scientific Officer, DiaCarta)
Mike Klein (Chief Executive Officer, Genomenon)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the genome sequencing services and technology providers market in the mid to long term.

Chapter 3 provides a general overview of the concept of genome sequencing with information on its process workflow, types including whole genome, whole exome and targeted sequencing, epigenetics, metagenomics and RNA sequencing and a wide array of uses in clinical research. It further highlights the history and evolution of genome sequencing with details on first, second and third generation NGS platforms, and a brief outline of various applications of genome sequencing including cancer and biomarker research, precision medicine, diagnostics and forensics research. Further, it includes a discussion on the various limitations / constraints and future perspectives of this evolving segment of pharmaceutical industry.

Chapter 4 provides an overview of genome sequencing service providers landscape, featuring information on year of establishment, company size, geographical location and types of services offered (sanger sequencing, genotyping, whole genome sequencing, whole exome sequencing targeted sequencing and bioinformatics). Further, it provides details on the cost of services, sequencing systems used, average turn-around time and sequencing coverage, for certain types of sequencing-related services (whole genome, whole exome and targeted sequencing) offered by contract service providers.

Chapter 5 provides an overview of genome sequencing technologies landscape, featuring information on the type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in this domain, including information on year of establishment, company size and geographical location.

Chapter 6 provides an informed competitiveness analysis of the genome sequencing technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as types of applications, maximum sequencing output, maximum reads per run, maximum read length, quality score and cost of sequencer.

Chapter 7 includes brief profiles of prominent service providers engaged in this domain. Each profile provides a brief overview of the company, its financial information (if available), a detailed description of services offered, recent developments and an informed future outlook.

Chapter 8 includes brief profiles of prominent technology developers engaged in this domain, featuring an overview of the company, its financial information (if available), a detailed description of its proprietary technology platform(s), recent developments and an informed future outlook.

Chapter 9 provides an in-depth patent analysis to provide an overview on how the industry has evolved from the R&D perspective. For this analysis, we looked at the patents related to genome sequencing that have been published since 2015. The analysis also highlights key information associated with these patents, including publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players, patent characteristics and geography.

Chapter 10 provides an analysis of completed, ongoing and planned clinical studies related to genome sequencing. The trials were analyzed on the basis of various relevant parameters, such as on registration year, type of sponsors / collaborators, current status of trials, type of study design, target therapeutic area, type of application, regional distribution of clinical trials and enrolled patient population.

Chapter 11 presents an analysis of the various genome sequencing-focused initiatives of ten big pharma players (out of top 20 established pharmaceutical players), highlighting the key focus areas of such companies along with information on funding, collaboration and acquisition activity.

Chapter 12 presents a case study on various national and international government sponsored initiatives related to genome sequencing, analyzed on the basis of year of initiation, type of investors, type of participant organization, research objectives, geographical distribution, region-specific data access policies and key focus areas of research.

Chapter 13 presents a detailed market forecast, highlighting the future potential of the genome sequencing services and technology market till the year 2030. The chapter features the likely distribution of the opportunity across [A] application areas (diagnostics, drug discovery, precision medicine and others), [B] end-users (hospitals and clinics, academics and research institutes, pharmaceuticals companies and others), [C] types of technologies (sequencing by synthesis, ion semiconductor, single-molecule real-time sequencing, nanopore and others), [D] types of services (whole genome sequencing, whole exome sequencing and targeted sequencing) and [E] key geographical regions (North America, Asia-Pacific, Europe, and rest of the world).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Genome Sequencing
3.3. Types of Genome Sequencing
3.4. History and Evolution of Genome Sequencing
3.4.1. First Generation DNA Sequencers
3.4.2. High Throughput-Next Generation Sequencing (HT-NGS)
3.4.2.1. Second Generation HT-NGS Platforms
3.4.2.2. Third Generation HT-NGS Platforms
3.4.2.2.1. Heliscope™ Single Molecule Sequencer
3.4.2.2.2. Single Molecule Real Time (SMRT™) Sequencer
3.4.2.2.3. Single Molecule Real Time (RNAP) Sequencer
3.4.2.2.4. Nanopore DNA Sequencer
3.4.2.2.5. Multiplex Polony Technology
3.4.2.2.6. The Ion Torrent Sequencing Technology

3.5. Practical Relevance of Genome Sequencing
3.5.1. Identification of Single Nucleotide Variants
3.5.2. Identification of Large Structural Variants
3.5.3. Variant Quality Control and Genotype Validation
3.5.4. Haplotype Phasing

3.5.3. Comparison of Available Genome Sequencing Technologies

3.6. Applications of Genome Sequencing
3.6.1. Cancer and Affiliated Biomarker Research
3.6.2. Diagnostics
3.6.3. Personalized / Precision Medicine
3.6.4. Forensics

3.7. Challenges Associated with Genome Sequencing
3.8. Future Perspectives

4. GENOME SEQUENCING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Genome Sequencing Service Providers: Market Landscape of Industry
Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Type of Services Offered
4.2.4.1. Whole Genome Sequencing Services
4.2.4.2. Whole Exome Sequencing Services
4.2.4.3. Targeted Sequencing Services

4.3. Genome Sequencing Service Providers: Market Landscape of Non-Industry Players
Industry Players
4.3.1. Analysis by Year of Establishment
4.3.3. Analysis by Geographical Location
4.3.4. Analysis by Type of Services
4.3.4.1. Whole Genome Sequencing Services
4.3.4.2. Whole Exome Sequencing Services
4.3.4.3. Targeted Sequencing Services

5. GENOME SEQUENCING TECHNOLOGIES: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Genome Sequencing Technologies: Overall Market Landscape
5.2.1. Analysis by Type of Application
5.2.2. Analysis by Maximum Sequencing Output
5.2.3. Analysis by Maximum Reads per Run
5.2.4. Analysis by Type of Sequencing Technique
5.2.5. Analysis of Technology Providers by Year of Establishment
5.2.6. Analysis of Technology Providers by Company Size
5.2.7. Analysis of Technology Providers by Geographical Location

6. PLATFORM COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.2.1. Platform Competitiveness Analysis: Peer Group I
6.2.2. Platform Competitiveness Analysis: Peer Group II
6.2.3. Platform Competitiveness Analysis: Peer Group III
6.2.4. Platform Competitiveness Analysis: Peer Group IV

7. COMPANY PROFILES: GENOME SEQUENCING SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Admera Health
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Applied Biological Materials
7.3.1. Company Overview
7.3.2. Services Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. BGI Genomics
7.4.1. Company Overview
7.4.2. Services Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. CD Genomics
7.5.1. Company Overview
7.5.2. Services Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. DNA Link
7.6.1. Company Overview
7.6.2. Services Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. Eurofins Genomics (Eurofins Scientific)
7.7.1. Company Overview
7.7.2. Services Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. Fulgent Genetics
7.8.1. Company Overview
7.8.2. Services Portfolio
7.8.3. Recent Developments and Future Outlook

7.9. Gene by Gene
7.9.1. Company Overview
7.9.2. Services Portfolio
7.9.3. Recent Developments and Future Outlook

7.10. GENEWIZ
7.10.1. Company Overview
7.10.2. Services Portfolio
7.10.3. Recent Developments and Future Outlook

7.11. MedGenome
7.11.1. Company Overview
7.11.2. Services Portfolio
7.11.3. Recent Developments and Future Outlook

7.12. Novogene
7.12.1. Company Overview
7.12.2. Services Portfolio
7.12.3. Recent Developments and Future Outlook

7.13. Omega Biosciences
7.13.1. Company Overview
7.13.2. Services Portfolio
7.13.3. Recent Developments and Future Outlook

7.14. Psomagen
7.14.1. Company Overview
7.14.2. Services Portfolio
7.14.3. Recent Developments and Future Outlook

7.15. Veritas Genetics
7.15.1. Company Overview
7.15.2. Services Portfolio
7.15.3. Recent Developments and Future Outlook

7.16. Xcerlis Labs
7.16.1. Company Overview
7.16.2. Services Portfolio
7.16.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: GENOME SEQUENCING TECHNOLOGY PROVIDERS
8.1. Chapter Overview

8.2. Illumina
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.3.1. iSeq 100™ System
8.2.3.2. MiniSeq™ System
8.2.3.3. MiSeq® System
8.2.3.4. NextSeq® Series
8.2.3.5. NextSeq 6000® System
8.2.4. Recent Developments and Future Outlook

8.3. Oxford Nanopore Technologies
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.3.1. MinION™ System
8.3.3.2. GridION™ System
8.3.3.3. PromethION™ System
8.3.4. Recent Developments and Future Outlook

8.4. Thermo Fisher Scientific
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Product Portfolio
8.4.3.1. Ion S5™ Systems
8.4.3.2. Ion GeneStudio S5™ System
8.4.3.3. SeqStudio™ System
8.4.3.4. Applied Biosystems® 3500 System
8.4.3.5. Ion PGM™ System
8.4.3.6. Ion Proton™ System
8.4.4. Recent Developments and Future Outlook

9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Genome Sequencing: Analysis of Patent Portfolio
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Issuing Authority / Patent Offices Involved
9.3.3. Analysis by CPC Symbols
9.4. Emerging Focus Areas
9.5. Leading Players: Analysis by Number of Patents

9.6. Genome Sequencing: Patent Benchmarking Analysis
9.6.1. Analysis by Patent Characteristics
9.6.2. Analysis by Geography
9.7. Patent Valuation Analysis

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Sequencing: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Registration Year and Geography
10.3.3. Analysis by Type of Sponsors / Collaborators
10.3.4. Analysis by Trial Status
10.3.5. Analysis by Trial Phase
10.3.6. Analysis by Type of Study Design
10.3.7. Analysis by Target Therapeutic Area
10.3.8. Analysis by Type of Application
10.3.10. Analysis by Target Therapeutic Area and Type of Application
10.3.11. Analysis by Number of Trials and Geography
10.3.12. Analysis by Enrolled Patient Population and Geography
10.3.13. Analysis by Number of Trials, Trial Status and Geography
10.3.14. Analysis by Enrolled Patient Population, Trial Status and Geography

11. GENOME SEQUENCING RELATED INITIATIVES OF BIG PHARMA PLAYERS
11.1. Chapter Overview
11.2. Scope and Methodology
11.2.1. Analysis by Type of Initiative
11.2.2. Analysis by Type of Collaboration
11.2.3. Analysis by Focus Area
11.2.4. Leading Players: Analysis by Number of Initiatives

12. CASE STUDY: GOVERNMENT SPONSORED INITIATIVES
12.1. Chapter Overview
12.2. Government Sponsored Initiatives
12.2.1. Analysis by Study Status
12.2.2. Analysis by Study Start Year
12.2.3. Analysis by Geographical Scope
12.2.4. Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
12.2.5. Analysis by Research Objective
12.2.6. Analysis by Focus Area
12.2.7. Analysis by Type of Players
12.2.8. Analysis by Type of Investors
12.2.9. Analysis by Region-specific Data Accessibility

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Overall Next Generation Sequencing Market, 2020-2030
13.3. Next Generation Sequencing Market: Distribution across Key Market Segments, 2020-2030
13.3.1. Genome Sequencing Products Market: Distribution by Type of Technology,2020 and 2030
13.3.2. Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030
13.4. Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030
13.5. Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030
13.6. Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030

13.6.1. Next Generation Sequencing Market in North America, 2020-2030
13.6.1.1. Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030
13.6.1.1.1. Next Generation Sequencing Market for Diagnostics in North America, 2020-2030
13.6.1.1.2. Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030
13.6.1.1.3. Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030
13.6.1.1.4. Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030
13.6.1.2. Next Generation Sequencing Market in North America: Distribution by End-Users,2020-2030

13.6.1.2.1. Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030
13.6.1.2.2. Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030
13.6.1.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030
13.6.1.2.4. Next Generation Sequencing Market for Other Users in North America, 2020-2030

13.6.2. Next Generation Sequencing Market in Europe, 2020-2030
13.6.2.1. Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030
13.6.2.1.1. Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030
13.6.2.1.2. Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030
13.6.2.1.3. Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030
13.6.2.1.4. Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030
13.6.2.2. Next Generation Sequencing Market in Europe: Distribution by End-Users, 2020-2030
13.6.2.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030
13.6.2.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030
13.6.2.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030
13.6.2.2.4. Next Generation Sequencing Market for Other Users in Europe, 2020-2030

13.6.3. Next Generation Sequencing Market in Asia-Pacific, 2020-2030
13.6.3.1. Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030
13.6.3.1.1. Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030
13.6.3.1.2. Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030
13.6.3.1.3. Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030
13.6.3.1.4. Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030
13.6.3.2. Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030
13.6.3.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030
13.6.3.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030
13.6.3.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030
13.6.3.2.4. Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030

13.6.4. Next Generation Sequencing Market in Rest of the World, 2020-2030
13.6.4.1. Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030
13.6.4.1.1. Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030
13.6.4.1.2. Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030
13.6.4.1.3. Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030
13.6.4.1.4. Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030
13.6.4.2. Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030
13.6.4.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030
13.6.4.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030
13.6.4.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030
13.6.4.2.4. Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030

14. FUTURE OPPORTUNITIES

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Steps Involved in Genome Sequencing
Figure 3.2 Types of Genome Sequencing
Figure 3.3 Types of Third Generation Sequencing Technologies
Figure 3.4 Applications of Genome Sequencing
Figure 4.1 Genome Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Genome Sequencing Service Providers (Industry Players): Distribution by Company Size
Figure 4.3 Genome Sequencing Service Providers (Industry Players): Distribution by Geography
Figure 4.4 Genome Sequencing Service Providers (Industry Players): Distribution by Type of Services Offered
Figure 4.5 Whole Genome Sequencing Services (Industry Players): Distribution by Technology Used
Figure 4.6 Whole Exome Sequencing Services (Industry Players): Distribution by Technology Used
Figure 4.7 Targeted Sequencing Services (Industry Players): Distribution by Technology Used
Figure 4.8 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
Figure 4.9 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Geography
Figure 4.10 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Type of Services Offered
Figure 4.11 Whole Genome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Figure 4.12 Whole Exome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Figure 4.13 Targeted Sequencing Services (Non-Industry Players): Distribution by Technology Used
Figure 5.1 Genome Sequencing Technologies: Distribution by Type of Application
Figure 5.2 Genome Sequencing Technologies: Distribution by Maximum Sequencing Output
Figure 5.3 Genome Sequencing Technologies: Distribution by Maximum Reads per Run
Figure 5.4 Genome Sequencing Technologies: Distribution by Sequencing Technique
Figure 5.5 Genome Sequencing Technology Providers: Distribution by Year of Establishment
Figure 5.6 Genome Sequencing Technology Providers: Distribution by Company Size
Figure 5.7 Genome Sequencing Technology Providers: Distribution by Geography
Figure 6.1 Platform Competitiveness Analysis: Peer Group I
Figure 6.2 Platform Competitiveness Analysis: Peer Group II
Figure 6.3 Platform Competitiveness Analysis: Peer Group III
Figure 6.4 Platform Competitiveness Analysis: Peer Group IV
Figure 8.1 Illumina: Annual Revenues, 2013- Q32020 (USD Million)
Figure 8.2 Illumina: Product Portfolio
Figure 8.3 Oxford Nanopore Technologies: Product Portfolio
Figure 8.4 Thermo Fisher Scientific: Annual Revenues, 2013-Q32020 (USD Million)
Figure 8.5 Thermo Fisher Scientific: Product Portfolio
Figure 9.1 Patent Portfolio: Distribution by Type of Patent
Figure 9.2 Patent Portfolio: Cumulative Distribution by Publication Year
Figure 9.4 Patent Portfolio: Distribution by Geographical Region
Figure 9.5 Patent Portfolio: Distribution by CPC Symbols
Figure 9.6 Patent Portfolio: Emerging Focus Areas
Figure 9.7 Leading Players: Distribution by Size of Patent Portfolio
Figure 9.8 Patent Portfolio: Benchmarking by Patent Characteristics
Figure 9.9 Patent Portfolio: Benchmarking by International Patents
Figure 9.10 Patent Portfolio: Distribution by Geography and Type of Patent
Figure 9.11 Patent Portfolio: Distribution by Patent Age
Figure 9.12 Patent Portfolio: Valuation Analysis
Figure 10.1 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Trial Registration Year
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 10.3 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Study Start Year
Figure 10.4 Clinical Trial Analysis: Distribution by Type of Sponsors / Collaborators
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.6 Clinical Trial Analysis: Distribution by Type of Study Design
Figure 10.7 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Application
Figure 10.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area and Type of Application
Figure 10. 10 Clinical Trial Analysis: Distribution by Number of Trials and Geography
Figure 10.11 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Geography
Figure 10.12 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Figure 10.13 Clinical Trial Analysis: Distribution by Enrollment Patient Population, Trial Status and Geography
Figure 11.1 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 11.2 Big Pharma Initiatives: Heat Map Analysis based on Type of Initiative
Figure 11.3 Big Pharma Initiatives: Distribution by Type of Collaboration
Figure 11.4 Big Pharma Initiatives: Heat Map Analysis based on Type of Collaboration
Figure 11.5 Big Pharma Initiatives: Distribution by Focus Area
Figure 11.6 Big Pharma Initiatives: Heat Map Analysis based on Focus Area
Figure 11.7 Leading Players: Distribution by Number of Initiatives
Figure 12.1 Government Sponsored Initiatives: Distribution by Study Status
Figure 12.2 Government Sponsored Initiatives: Distribution by Study Start Year
Figure 12.3 Government Sponsored Initiatives: Distribution by Geographical Scope
Figure 12.4 World Map Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
Figure 12.5 Government Sponsored Initiatives: Distribution by Research Objective
Figure 12.6 Government Sponsored Initiatives: Distribution by Focus Area
Figure 12.7 Government Sponsored Initiatives: Distribution by Type of Players
Figure 12.8 Government Sponsored Initiatives: Distribution by Type of Investors
Figure 13.1 Overall Next Generation Sequencing Market, 2020-2030 (USD Billion)
Figure 13.2 Next Generation Sequencing Market: Distribution by Key Market Segments, 2020-2030 (USD Billion)
Figure 13.3 Genome Sequencing Products Market: Distribution by Type of Technology, 2020 and 2030 (USD Billion)
Figure 13.4 Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030 (USD Billion)
Figure 13.5 Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030 (USD Billion)
Figure 13.6 Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030 (USD Billion)
Figure 13.7 Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030 (USD Billion)
Figure 13.8 Next Generation Sequencing Market in North America, 2020-2030 (USD Billion)
Figure 13.9 Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.10 Next Generation Sequencing Market for Diagnostics in North America, 2020-2030 (USD Billion)
Figure 13.11 Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030 (USD Billion)
Figure 13.12 Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030 (USD Billion)
Figure 13.13 Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030 (USD Billion)
Figure 13.14 Next Generation Sequencing Market in North America: Distribution by End-Users, 2020-2030 (USD Billion)
Figure 13.15 Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030 (USD Billion)
Figure 13.16 Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030 (USD Billion)
Figure 13.17 Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030 (USD Billion)
Figure 13.18 Next Generation Sequencing Market for Other Users in North America, 2020-2030 (USD Billion)
Figure 13.19 Next Generation Sequencing Market in Europe, 2020-2030 (USD Billion)
Figure 13.20 Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.21 Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030 (USD Billion)
Figure 13.22 Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030 (USD Billion)
Figure 13.23 Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030 (USD Billion)
Figure 13.24 Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030 (USD Billion)
Figure 13.25 Next Generation Sequencing Market in Europe: Distribution by End Users, 2020- 2030 (USD Billion)
Figure 13.26 Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030 (USD Billion)
Figure 13.27 Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030 (USD Billion)
Figure 13.28 Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030 (USD Billion)
Figure 13.29 Next Generation Sequencing Market for Other Users in Europe, 2020-2030 (USD Billion)
Figure 13.30 Next Generation Sequencing Market in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.31 Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.32 Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.33 Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.34 Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.35 Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.36 Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030 (USD Billion)
Figure 13.37 Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.38 Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.39 Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.40 Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.41 Next Generation Sequencing Market in Rest of the World, 2020-2030 (USD Billion)
Figure 13.42 Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.43 Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030 (USD Billion)
Figure 13.44 Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030 (USD Billion)
Figure 13.45 Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030 (USD Billion)
Figure 13.46 Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030 (USD Billion)
Figure 13.47 Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030 (USD Billion)
Figure 13.48 Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030 (USD Billion)
Figure 13.49 Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030 (USD Billion)
Figure 13.50 Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030 (USD Billion)
Figure 13.51 Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030 (USD Billion)

List Of Tables

Table 3.1 Comparison of Available Genome Sequencing Technologies
Table 4.1 Genome Sequencing Service Providers: List of Industry Players
Table 4.2 Genome Sequencing Service Providers (Industry Players): Information on Type of Services Offered
Table 4.3 Genome Sequencing Service Providers (Industry Players): Information on Whole Genome Sequencing Services
Table 4.4 Genome Sequencing Service Providers (Industry Players): Information on Whole Exome Sequencing Services
Table 4.5 Genome Sequencing Service Providers (Industry Players): Information on Targeted Sequencing Services
Table 4.6 Genome Sequencing Service Providers: List of Non-Industry Players
Table 4.7 Genome Sequencing Service Providers (Non-Industry Players): Information on Type of Services Offered
Table 4.8 Genome Sequencing Service Providers (Non-Industry Players): Information on Whole Genome Sequencing Services
Table 4.9 Genome Sequencing Service Providers (Non-Industry Players): Information on Whole Exome Sequencing Services
Table 4.10 Genome Sequencing Service Providers (Non-Industry Players): Information on Targeted Sequencing Services
Table 5.1 Genome Sequencing: List of Available Technologies
Table 5.2 Genome Sequencing Technologies: Additional Technology Specifications
Table 5.3 List of Genome Sequencing Technology Providers
Table 7.1 BGI: Company Snapshot
Table 7.2 BGI Genomics: Recent Developments and Future Outlook
Table 7.3 Veritas: Company Snapshot
Table 7.4 Veritas: Recent Developments and Future Outlook
Table 7.5 Novogene: Company Snapshot
Table 7.6 Novogene: Recent Developments and Future Outlook
Table 7.7 GENEWIZ: Company Snapshot
Table 7.8 GENEWIZ: Recent Developments and Future Outlook
Table 7.9 Eurofins Genomics: Company Snapshot
Table 7.10 Eurofins Genomics: Recent Developments and Future Outlook
Table 7.11 CD Genomics: Company Snapshot
Table 7.12 CD Genomics: Recent Developments and Future Outlook
Table 7.13 DNA Link: Company Snapshot
Table 7.14 DNA Link: Recent Developments and Future Outlook
Table 7.15 Applied Biological Materials: Company Snapshot
Table 7.16 Applied Biological Materials: Recent Developments and Future Outlook
Table 7.17 Admera Health: Company Snapshot
Table 7.18 Admera Health: Recent Developments and Future Outlook
Table 7.19 Gene by Gene: Company Snapshot
Table 7.20 Gene by Gene: Recent Developments and Future Outlook
Table 7.21 Xcerlis Labs: Company Snapshot
Table 7.22 Xcerlis Labs: Recent Developments and Future Outlook
Table 7.23 Fulgent Genetics: Company Snapshot
Table 7.24 Fulgent Genetics: Recent Developments and Future Outlook
Table 7.25 Omega Biosciences: Company Snapshot
Table 7.26 Omega Biosciences: Recent Developments and Future Outlook
Table 7.27 Med-Genome: Company Snapshot
Table 7.28 Med-Genome: Recent Developments and Future Outlook
Table 7.29 Psomagen: Company Snapshot
Table 7.30 Psomagen: Recent Developments and Future Outlook
Table 8.1 Illumina: Recent Developments and Future Outlook
Table 8.2 Oxford Nanopore Technologies: Recent Developments and Future Outlook
Table 8.3 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.1 Patent Portfolio: CPC Symbols
Table 9.2 Patent Portfolio: Most Popular CPC Symbols
Table 9.3 Patent Portfolio: List of Top 10 CPC Symbols
Table 9.4 Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 9.5 Patent Portfolio: List of Relatively Higher Value Patents
Table 12.1 Genome Sequencing: List of Government Sponsored Initiatives
Table 12.2 Government Sponsored Initiatives: Information on Research Objectives
Table 12.3 Government Sponsored Initiatives: Additional Details
Table 12.4 Government Sponsored Initiatives: Information on Region-Specific Data Accessibility
Table 15.1 Genome Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Table 15.2 Genome Sequencing Service Providers (Industry Players): Distribution by Company Size
Table 15.3 Genome Sequencing Service Providers (Industry Players): Distribution by Geography
Table 15.4 Genome Sequencing Service Providers (Industry Players): Distribution by Type of Services Offered
Table 15.5 Whole Genome Sequencing Services (Industry Players): Distribution by Technology Used
Table 15.6 Whole Exome Sequencing Services (Industry Players): Distribution by Technology Used
Table 15.7 Targeted Sequencing Services (Industry Players): Distribution by Technology Used
Table 15.8 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
Table 15.9 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Geography
Table 15.10 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Type of Services Offered
Table 15.11 Whole Genome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Table 15.12 Whole Exome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Table 15.13 Targeted Sequencing Services (Non-Industry Players): Distribution by Technology Used
Table 15.14 Genome Sequencing Technologies: Distribution by Type of Application
Table 15.15 Genome Sequencing Technologies: Distribution by Maximum Sequencing Output
Table 15.16 Genome Sequencing Technologies: Distribution by Maximum Reads per Run
Table 15.17 Genome Sequencing Technologies: Distribution by Sequencing Technique
Table 15.18 Genome Sequencing Technology Providers: Distribution by Year of Establishment
Table 15.19 Genome Sequencing Technology Providers: Distribution by Company Size
Table 15.20 Genome Sequencing Technology Providers: Distribution by Geography
Table 15.21 Illumina: Annual Revenues, 2013- Q32020 (USD Million)
Table 15.22 Thermo Fisher Scientific: Annual Revenues, 2013-Q32020 (USD Million)
Table 15.23 Patent Portfolio: Distribution by Type of Patent
Table 15.24 Patent Portfolio: Cumulative Distribution by Publication Year
Table 15.25 Patent Portfolio: Distribution by Geographical Region
Table 15.26 Patent Portfolio: Distribution by CPC Symbols
Table 15.27 Leading Players: Distribution by Size of Patent Portfolio
Table 15.28 Patent Portfolio: Benchmarking by International Patents
Table 15.29 Patent Portfolio: Distribution by Geography and Type of Patent
Table 15.30 Patent Portfolio: Distribution by Patent Age
Table 15.31 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Trial Registration Year
Table 15.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 15.33 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Study Start Year
Table 15.34 Clinical Trial Analysis: Distribution by Type of Sponsors / Collaborators
Table 15.35 Clinical Trial Analysis: Distribution by Trial Status
Table 15.36 Clinical Trial Analysis: Distribution by Type of Study Design
Table 15.37 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 15.38 Clinical Trial Analysis: Distribution by Type of Application
Table 15.39 Clinical Trial Analysis: Distribution by Target Therapeutic Area and Type of Application
Table 15.40 Big Pharma Initiatives: Distribution by Type of Initiative
Table 15.41 Big Pharma Initiatives: Distribution by Type of Collaboration
Table 15.42 Big Pharma Initiatives: Distribution by Focus Area
Table 15.43 Leading Players: Distribution by Number of Initiatives
Table 15.44 Government Sponsored Initiatives: Distribution by Study Status
Table 15.45 Government Sponsored Initiatives: Distribution by Study Start Year
Table 15.46 Government Sponsored Initiatives: Distribution by Geographical Scope
Table 15.47 World Map Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
Table 15.48 Government Sponsored Initiatives: Distribution by Research Objective
Table 15.49 Government Sponsored Initiatives: Distribution by Focus Area
Table 15.50 Government Sponsored Initiatives: Distribution by Type of Players
Table 15.51 Government Sponsored Initiatives: Distribution by Type of Investors
Table 15.52 Overall Next Generation Sequencing Market, 2020-2030 (USD Billion)
Table 15.53 Next Generation Sequencing Market: Distribution by Key Market Segments, 2020-2030 (USD Billion)
Table 15.54 Genome Sequencing Products Market: Distribution by Type of Technology, 2020 and 2030 (USD Billion)
Table 15.55 Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030 (USD Billion)
Table 15.56 Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030 (USD Billion)
Table 15.57 Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030 (USD Billion)
Table 15.58 Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030 (USD Billion)
Table 15.59 Next Generation Sequencing Market in North America, 2020-2030 (USD Billion)
Table 15.60 Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.61 Next Generation Sequencing Market for Diagnostics in North America, 2020-2030 (USD Billion)
Table 15.62 Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030 (USD Billion)
Table 15.63 Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030 (USD Billion)
Table 15.64 Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030 (USD Billion)
Table 15.65 Next Generation Sequencing Market in North America: Distribution by End-Users, 2020-2030 (USD Billion)
Table 15.66 Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030 (USD Billion)
Table 15.67 Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030 (USD Billion)
Table 15.68 Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030 (USD Billion)
Table 15.69 Next Generation Sequencing Market for Other Users in North America, 2020-2030 (USD Billion)
Table 15.70 Next Generation Sequencing Market in Europe, 2020-2030 (USD Billion)
Table 15.71 Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.72 Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030 (USD Billion)
Table 15.73 Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030 (USD Billion)
Table 15.74 Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030 (USD Billion)
Table 15.75 Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030 (USD Billion)
Table 15.76 Next Generation Sequencing Market in Europe: Distribution by End Users, 2020- 2030 (USD Billion)
Table 15.77 Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030 (USD Billion)
Table 15.78 Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030 (USD Billion)
Table 15.79 Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030 (USD Billion)
Table 15.80 Next Generation Sequencing Market for Other Users in Europe, 2020-2030 (USD Billion)
Table 15.81 Next Generation Sequencing Market in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.82 Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.83 Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.84 Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.85 Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.86 Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.87 Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030 (USD Billion)
Table 15.88 Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.89 Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.90 Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.91 Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.92 Next Generation Sequencing Market in Rest of the World, 2020-2030 (USD Billion)
Table 15.93 Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.94 Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030 (USD Billion)
Table 15.95 Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030 (USD Billion)
Table 15.96 Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030 (USD Billion)
Table 15.97 Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030 (USD Billion)
Table 15.98 Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030 (USD Billion)
Table 15.99 Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030 (USD Billion)
Table 15.100 Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030 (USD Billion)
Table 15.101 Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030 (USD Billion)
Table 15.102 Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

1st base
23andMe
AbbVie
AbCellera
Active Motif
Activiomics
Adaltis
Admera Health
Agiomix
AgriGenome Labs
AKESOgen
Almac Group
American Association for Cancer Research
Amgen
Annoroad Gene Technology
ANTISEL
Applied Biological Materials
Arizona Genomics Institute
Arizona Technology Enterprises
Arthritis Research UK
ARUP Laboratories
Asper Biogene
AstraZeneca
Asuragen
Auragen
Australian Genome Research Facility
BaseClear
Bayer
BGI
Bio Basic
BioAnalytical Services Laboratory (University of Maryland)
BIOFIDAL
Bionano Genomics
Biosearch Technologies
Biotechnology Center (University of Wisconsin)
Boehringer Ingelheim
Bristol-Myers Squibb
Broad Institute
C-Camp (Next Generation Genomics facility)
CD Genomics
CeGaT
Celsius Therapeutics
CEN4GEN
Center for Applied Genomics (Children's Hospital of Philadelphia)
Center for biomedical research Support (University of Texas)
Centogene
Centre for Genome Biology (University of Bologna)
Centre for Genomic Research (University of Liverpool)
Chromous
Cold Spring Harbor Laboratory Next Generation Genomics Core
Columbia Genome Center
Columbia University
Complete Genomics
Computomics
Contextual Genomics
CosmosID
Daiichi Sankyo
Dante Labs
DBS Genomics (Durham University)
DC3 Therapeutics
De Novo Genomics
deCODE genetics
DiaCarta
Diagnomics
Diversigen
DNA Genotek
DNA Link
DNA Sequencing & Genotyping Center Delaware Biotechnology Institute
DNA Sequencing and Gene Analysis Center (University of Washington)
DNA Sequencing Center (Brigham Young University)
DNAnexus
DNAVision
Dow Agrosciences
Earlham Institute
Edinburgh Genomics
Epigenomics Core
Eurofins Genomics
Fasteris
Ferring Pharmaceuticals
Firalis
Five Prime Therapeutics
Foundation Medicine
Frasergen Bioinformatics
Fulgent Genetics
Full Genomes
Functional Genomics Center Zurich (University of Zürich)
GenapSys
Gencove
Gene by Gene
Genentech
GenePlanet
GeneTech
GENEWIZ
Genia Technologies
Genialis
Genome
Genome Quebec Innovation Centre
Genome Technology Access Center (University of Washington)
GenomeFan
GenomeScan
GenomeStream
Genomics and Sequencing Center (University of Rhode Island)
Genomics Evidence Neoplasia Information Exchange
Genomics Medicine Ireland
Genomics Personalized Health
Genomics Sequencing Service Center (Stanford Medicine)
Genomix4Life
Genoptix
Genosity
Genotypic Technology
Gilead Sciences
GlaxoSmithKline
GRAIL
Halozyme Therapeutics
Harvard University
Health Wadsworth Center
Healthcare and Bioscience iNet
HistoGenetics
Horizon Discovery
HudsonAlpha Genome Sequencing Center
Human Genome Sciences
Human Longevity
Icahn Institute for Data Science and Genomic Technology
Illumina
Inotrem
Institute for Food Safety and Health (Illinois Institute of Technology)
Integrative Genomics Core (City of Hope)
International Wheat Genome Sequencing Consortium
Jan-Willem de Gier (Stockholm University)
Johns Hopkins University
Johnson and Johnson
Jouvene
Kapa Biosystems
Kazusa DNA Research Institute
KCCG Sequencing Laboratory (Garvan Institute of Medical Research)
LC Sciences
Loop Genomics
Loxo Oncology
Lucigen
Macrogen
Maryland Genomics
Massachusetts General Hospital
Massachusetts Institute of Technology
Massey Genome Service (Massey University)
Max Planck-Genome-centre Cologne
McDonnell Genome Institute (Washington University)
McGill University
MedGenome
MedImmune (a subsidiary of AstraZeneca)
Medivir
Merck
MGI Tech
Microba
Microgenomics
Microsynth
MNG Laboratories (Medical Neurogenetics)
MOgene
MolDiag Solutions
Molecular Biology and Genomics Core (Washington State University)
MongoDB
MRC Human Genetics Unit (University of Edinburgh)
myGenomics
Myriad Genetics
Nabsys
National Genomics Infrastructure (University of Uppsala)
National Instrumentation Center for Environmental Management
Nebula Genomics
New York Genome Center
Next Generation Sequencing Core (Oklahoma Medical Research Foundation)
Next Generation Sequencing Facility (University of Leeds)
Novartis
Novogene
Nucleics
Nucleome
Ocean Genome Legacy
Okairos and Conatus
Omega Bioservices
Oncimmune
OpGen
Otogenetics
Oxford Genomics Centre
Oxford Nanopore Technologies
Oxford University Consortium
Pacific Biosciences
Partners HealthCare Personalized Medicine
PerkinElmer Genomics
Pfizer
Phalanx Biotech
Phoenix Molecular Designs
Pierre Fabre
Protein and Nucleic Acid Facility
Psomagen
Q2 Solutions
QIAGEN
Quick Biology
Rady Children's Institute for Genomic Medicine
Ramaciotti Centre for Genomics (UNSW Sydney)
RAPiD Genomics
REPROCELL
Roche
RTLGenomics
San Diego Supercomputer Center
Sanofi
Scripps Translational Science Institute
Second Genome
SeqLL
SeqMatic
Sequencing Center
Shanghai OE Biotech
Source BioScience
SRM
Stanford University
StarSEQ
Stratos Genomics
Synbio Technologies
Technology Center for Genomics & Bioinformatics (UCLA)
Texas A&M AgriLife
Theragen Etex Bio
Thermo Fisher Scientific
Toldot Genetics
UCB
UCLA Clinical Genomics Center
UK's Medical Research Foundation
United Therapeutics
University of California
University of Leicester
University of London
University of Minnesota Genomics Center
University of Nottingham
University of Utah Health
Veritas
Waksman Institute of Microbiology (Rutgers University)
Wellcome Sanger Institute
WuXi NextCODE
Xcelris Labs
Yaazh Xenomics
Yale Center for Genome Analysis (Yale School of Medicine)
Yikon Genomics

Segmentation

The USD 19 billion (by 2030) financial opportunity within the next generation sequencing market has been analyzed across the following segments:

Type of Offering
- Products
- Services
Type of sequencing technology used
- Sequencing by synthesis (SBS)
- Ion semiconductor sequencing
- Single Molecule, Real-Time (SMRT) sequencing
- Nanopore sequencing
- Others
Key application areas
- Diagnostics
- Drug discovery and personalized medicine
- Reproductive health
End-users
- Academic and research institutes
- Hospitals and clinics
- Pharmaceutical companies
- Others

PRICING DETAILS

Single-User License USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

One Location Site License USD 7,999

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

Enterprise License USD 15,999

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

Next Generation Sequencing